Danuglipron

Mechanism

Danuglipron is a non-peptide small molecule that acts as a selective GLP-1 receptor agonist. It binds to and activates the GLP-1 (glucagon-like peptide-1) receptor, mimicking the action of endogenous GLP-1. This stimulation enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon secretion, delays gastric emptying, and reduces appetite through central nervous system effects. Unlike peptide-based GLP-1 agonists (e.g., semaglutide), danuglipron's small-molecule structure allows oral bioavailability without degradation in the gastrointestinal tract.

Evidence base

Evidence Grade: Moderate

Phase 2b clinical trial data demonstrated statistically significant weight loss and HbA1c reduction with danuglipron IR at 32 weeks. However, the programme was discontinued before Phase 3 confirmatory trials could be completed. Key limitations:

• High discontinuation rates due to gastrointestinal adverse events (nausea, vomiting)
• Weight-loss magnitude did not sufficiently differentiate from existing injectable GLP-1 agonists
• Twice-daily dosing was less convenient than once-weekly injectable alternatives
• No long-term cardiovascular outcome trial data

A modified-release formulation (PF-07954634) is in early-phase development to address tolerability and dosing frequency concerns.

Protocols

Danuglipron was studied as an immediate-release oral tablet with twice-daily dosing. The Phase 2 trial used gradual dose titration from 50 mg twice daily up to target doses of 80–240 mg twice daily. This information describes clinical trial design only; danuglipron was never approved and is not available for use. Not medical advice.

UK legal status

Danuglipron is not approved by the MHRA, EMA, or FDA. It was never submitted for regulatory approval due to programme discontinuation. It is not legally available outside of clinical trial settings. Possession or supply outside clinical trial frameworks would fall under standard UK pharmaceutical legislation.

Vendor notes

Danuglipron is not commercially available and no legitimate UK vendor sells this compound. Any supplier claiming to offer danuglipron should be treated with extreme caution.